Literature DB >> 18712364

Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice.

Meredith A Fox1, Catherine L Jensen, Helen T French, Alison R Stein, Su-Jan Huang, Teresa J Tolliver, Dennis L Murphy.   

Abstract

RATIONALE: Serotonin transporter (SERT) knockout (-/-) mice have an altered phenotype in adulthood, including high baseline anxiety and depressive-like behaviors, associated with increased baseline extracellular serotonin levels throughout life.
OBJECTIVES: To examine the effects of increases in serotonin following the administration of the serotonin precursor 5-hydroxy-L-tryptophan (5-HTP) in SERT wild-type (+/+), heterozygous (+/-), and -/- mice.
RESULTS: 5-HTP increased serotonin in all five brain areas examined with approximately 2- to 5-fold increases in SERT+/+ and +/- mice, and with greater 4.5- to 11.7-fold increases in SERT-/- mice. Behaviorally, 5-HTP induced exaggerated serotonin syndrome behaviors in SERT-/-, mice with similar effects in male and female mice. Studies suggest promiscuous serotonin uptake by the dopamine transporter (DAT) in SERT-/- mice, and here, the DAT blocker GBR 12909 enhanced 5-HTP-induced behaviors in SERT-/- mice. Physiologically, 5-HTP induced exaggerated temperature effects in SERT-deficient mice. The 5-HT1A antagonist WAY 100635 decreased 5-HTP-induced hypothermia in SERT+/+ and +/- mice with no effect in SERT-/- mice, whereas the 5-HT7 antagonist SB 269970 decreased this exaggerated response in SERT-/- mice only. WAY 100635 and SB 269970 together completely blocked 5-HTP-induced hypothermia in SERT+/- and -/- mice.
CONCLUSIONS: These studies demonstrate that SERT-/- mice have exaggerated neurochemical, behavioral, and physiological responses to further increases in serotonin, and provide the first evidence of intact 5-HT7 receptor function in SERT-/- mice, with interesting interactions between 5-HT1A and 5-HT7 receptors. As roles for 5-HT7 receptors in anxiety and depression were recently established, the current findings have implications for understanding the high anxiety and depressive-like phenotype of SERT-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18712364      PMCID: PMC2584159          DOI: 10.1007/s00213-008-1268-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  81 in total

1.  Abnormal trafficking and subcellular localization of an N-terminally truncated serotonin transporter protein.

Authors:  A Ravary; A Muzerelle; M Darmon; D L Murphy; R Moessner; K P Lesch; P Gaspar
Journal:  Eur J Neurosci       Date:  2001-04       Impact factor: 3.386

Review 2.  The medical benefit of 5-HT research.

Authors:  Brian J Jones; Thomas P Blackburn
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

3.  Sex hormone-dependent desensitization of 5-HT1A autoreceptors in knockout mice deficient in the 5-HT transporter.

Authors:  Saoussen Bouali; Alexis Evrard; Michel Chastanet; Klaus-Peter Lesch; Michel Hamon; Joëlle Adrien
Journal:  Eur J Neurosci       Date:  2003-10       Impact factor: 3.386

4.  Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.

Authors:  Anna Wesołowska; Agnieszka Nikiforuk; Katarzyna Stachowicz; Ewa Tatarczyńska
Journal:  Neuropharmacology       Date:  2006-07-07       Impact factor: 5.250

5.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

6.  5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter.

Authors:  Ying Qu; Nelly Villacreses; Dennis L Murphy; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2005-04-15       Impact factor: 4.530

7.  The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function.

Authors:  G M Goodwin; R J De Souza; A R Green
Journal:  Neuropharmacology       Date:  1985-12       Impact factor: 5.250

8.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

9.  Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development.

Authors:  Yanling Xu; Youssef Sari; Feng C Zhou
Journal:  Brain Res Dev Brain Res       Date:  2004-06-21

10.  Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice.

Authors:  Pascal Bonaventure; Diane Nepomuceno; Annette Kwok; Wenying Chai; Xavier Langlois; Rene Hen; Kimberly Stark; Nicholas Carruthers; Timothy W Lovenberg
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

View more
  28 in total

1.  TPH2 in the ventral tegmental area of the male rat brain.

Authors:  Nurgul Carkaci-Salli; Ugur Salli; Kara L Kuntz-Melcavage; Michael M Pennock; Hande Ozgen; Izel Tekin; Willard M Freeman; Kent E Vrana
Journal:  Brain Res Bull       Date:  2011-01-25       Impact factor: 4.077

2.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

Review 3.  Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.

Authors:  Dennis L Murphy; Pablo R Moya
Journal:  Curr Opin Pharmacol       Date:  2011-03-23       Impact factor: 5.547

4.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

5.  Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice.

Authors:  Mireille Basselin; Meredith A Fox; Lisa Chang; Jane M Bell; Dede Greenstein; Mei Chen; Dennis L Murphy; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

Review 6.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

7.  Platelet serotonin transporter function and heart rate variability in patients with panic disorder.

Authors:  Eun-Ho Kang; In-Soo Lee; Joo-Eon Park; Kyung-Jeong Kim; Bum-Hee Yu
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

Review 8.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

9.  Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice.

Authors:  Meredith A Fox; Catherine L Jensen; Dennis L Murphy
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-11       Impact factor: 5.176

10.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.